New Tools for Prostate Cancer Research

(London, UK), a company that is developing vaccines for prostate and other cancers.

"These new lines are important because they effectively double the material available to researchers,” explained Dr. James Eliason, head of research for Asterand. "Until now there have been only three prostate cancer lines commonly available for study. Each cell line represents a single patient and every patient is different so it is useful to examine different lines. Now we are offering three lines representing the disease plus three cell lines representing normal prostate tissue.”




Related Links:
Asterand
Onyvax